Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to SARS-CoV-2.
Adaptive has identified and characterized ultra-potent, neutralizing antibodies to SARS-CoV-2. Our antibodies can be considered for development as either differentiated monoclonal antibodies or as synergistic antibody cocktail to treat or prevent COVID-19.
Beyond COVID-19, Adaptive is exploring applications of TruAB discovery in other diseases, including autoimmunity.
© Adaptive Biotechnologies. All Rights Reserved.
Privacy Policy | Cookie Policy | Do Not Sell My Info (CA Residents) | Terms of Service | Code of Conduct
© Adaptive Biotechnologies. All Rights Reserved.
Privacy Policy | Cookie Policy | Do Not Sell My Info (CA Residents) | Terms of Service | Code of Conduct